Danish pharmaceutical major Novo Nordisk has officially launched its anti-obesity therapy Wegovy in India. The once-weekly injectable treatment is approved for long-term chronic weight management and for reducing the risk of major adverse cardiovascular events in adults.

Expanding beyond its leadership in the insulin segment, Novo Nordisk is introducing Wegovy across urban and rural markets nationwide, offering the product in all five approved dose strengths.

Vikrant Shrotriya - Managing Director, Novo Nordisk India said, “Obesity is not just a personal health concern—it is a chronic disease and a national epidemic that India cannot afford to ignore. Recognising this, we are proud to announce that we are bringing Wegovy® to Indians as a transformative and evidence-based therapeutic solution with the convenience of a world-class, state-of-the-art pen device. Additionally, we have an India-specific price with the benefit of same price for the first three dosing strengths. With this we are reaffirming our commitment to address India's growing burden of overweight and obesity.”

Wegovy will be available in a convenient, once-weekly pen injector, with dosage options of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The monthly cost of therapy will range between ₹17,345 and ₹26,050, depending on dosage.

The launch follows the success of the company’s diabetes therapy Ozempic and comes amid rising obesity rates in India, where nearly one in four adults is overweight or obese, increasing the risk of Type 2 diabetes and cardiovascular disease.

Novo Nordisk aims to reshape the obesity treatment landscape in India by equipping patients and healthcare providers with innovative, clinically proven solutions.